Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Nuvectis Pharma (NVCT) Income from Continuing Operations (2021 - 2026)

Nuvectis Pharma has reported Income from Continuing Operations over the past 6 years, most recently at 6050000.0 for Q1 2026.

  • Quarterly results put Income from Continuing Operations at 6050000.0 for Q1 2026, down 13.47% from a year ago — trailing twelve months through Mar 2026 was 27160000.0 (down 34.72% YoY), and the annual figure for FY2025 was 26442000.0, down 39.17%.
  • Income from Continuing Operations reached 6050000.0 in Q1 2026 per NVCT's latest filing, up from 7314000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2943000.0 in Q1 2022 and bottomed at 7462000.0 in Q3 2025.
  • Median Income from Continuing Operations over the past 5 years was 5877000.0 (2022), compared with a mean of 5461000.0.
  • Peak annual rise in Income from Continuing Operations hit 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
  • Over 5 years, Income from Continuing Operations stood at 6696000.0 in 2022, then grew by 1.11% to 6622000.0 in 2023, then grew by 5.65% to 6248000.0 in 2024, then decreased by 17.06% to 7314000.0 in 2025, then increased by 17.28% to 6050000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for NVCT at 6050000.0 in Q1 2026, 7314000.0 in Q4 2025, and 7462000.0 in Q3 2025.